Key Takeaways
- Visual acuity remained stable in eyes that switched to aflibercept-ayyh and improved in treatment-naïve eyes.
- Most treated eyes (91%) had previously received another anti-VEGF therapy before switching to aflibercept-ayyh.
- Safety findings were favorable, with only two cases of iritis reported
The biosimilar aflibercept-ayyh was associated with stable vision in patients who switched from other anti-VEGF therapies and improved vision in treatment-naïve patients, according to a real-world analysis.
The analysis included 1,000 consecutive eyes from 989 patients who received a total of 3,730 injections. Most eyes (91%) had previously been treated with another anti-VEGF therapy, while 9% were treatment-naïve.
The study population included eyes with neovascular age-related macular degeneration (58%), retinal vein occlusion (19%), diabetic macular edema (16%), and diabetic retinopathy (7%). Patients who switched therapies had received a median of 21 prior anti-VEGF injections and were followed for a median of 6 months, during which they received a median of 4 aflibercept-ayyh injections.
In eyes (n = 889) with at least 84 days of follow-up, mean visual acuity was maintained after switching from another anti-VEGF agent (logMAR 0.4 to 0.4; P = 0.96) and improved in treatment-naïve eyes (0.5 to 0.4; P < 0.01).
Safety outcomes were favorable. Confirmed adverse events included two cases of iritis (0.05% of injections). No cases of vitreous cells, endophthalmitis, retinal detachment, retinal vasculitis, or vitreous hemorrhage were observed.
Reference
Servin AE, McFadden I, Esmaeilkhanian H, et al. Real-World Utilization and Initial Experience with Aflibercept-ayyh (PAVBLU®) for Retinal Disorders in United States Retina Practices: A Descriptive Retrospective Analysis. Ophthalmol Ther. 2026;doi: 10.1007/s40123-026-01400-6. Epub ahead of print. PMID: 42223803.
Related Content
